Atrial fibrillation (AF), heart failure (HF) and acute coronary syndrome (ACS) are major drivers of cardiovascular disease (CVD), which causes more than 3.9 million deaths each year across Europe. Currently, the management of AF, HF and ACS is complicated by their complex aetiology and heterogeneous prognoses. There is a clear need for a better definition of CVD through improved biomarkers and endpoints, as well as its outcomes and prognoses. The BigData@Heart, a five-year project launched in March 2017, uniquely brings together 19 partners from academia, medical associations, pharmaceutical industry, SME’s and patient organizations to address these challenges. The consortium will develop a data-driven translational research platform which will be aiming at delivering clinically relevant disease phenotypes, scalable insights from real-world evidence, best-practices in drug development, and personalised medicines through advanced analytics.
Partners
- University Medical Center Utrecht
- Charité
- European Society of Cardiology
- European Heart Network
- University College London
- University of Cambridge
- International Consortium for Health Outcomes Measurement
- Fundación para la investigación del Hospital Clinico de la Comunidad Valenciana
- Karolinska Institutet
- Universitätsklinikum Hamburg-Eppendorf
- MLC Foundation
- University of Birmingham
- Uppsala University Hospital
- Bayer
- Novartis
- Servier
- Somalogic
- Vifor Pharma
- The Hyve